Invention Grant
- Patent Title: RNA antagonist compounds for the modulation of HER3
- Patent Title (中): 用于调节HER3的RNA拮抗剂化合物
-
Application No.: US12118271Application Date: 2008-05-09
-
Publication No.: US08268793B2Publication Date: 2012-09-18
- Inventor: Maj Hedtjarn
- Applicant: Maj Hedtjarn
- Applicant Address: DK Hersholm US NJ Piscataway
- Assignee: Santaris Pharma A/S,Enzon Pharmaceuticals, Inc.
- Current Assignee: Santaris Pharma A/S,Enzon Pharmaceuticals, Inc.
- Current Assignee Address: DK Hersholm US NJ Piscataway
- Agency: Stoel Rives LLP
- Main IPC: A01N43/04
- IPC: A01N43/04 ; C12Q1/68 ; C12P19/34 ; C07H21/02 ; C07H21/04
Abstract:
The invention relates to oligomer compounds (oligomers), which target HER3 mRNA in a cell, leading to reduced expression of HER3 and/or HER2 and/or EGFR. Reduction of HER3 and/or HER2 and/or EGFR expression is beneficial for a range of medical disorders, such hyperproliferative disorders (e.g., cancer). The invention provides therapeutic compositions comprising oligomers and methods for modulating the expression of HER3 and/or HER2 and/or EGFR using said oligomers, including methods of treatment.
Public/Granted literature
- US20080318894A1 RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF HER3 Public/Granted day:2008-12-25
Information query
IPC分类:
